Reports
3 reportsQuarterly reports, annual reports and year-end reports from Doktor.se, newest first.
Doktor.se delivers a strong first half of 2026 – summary of the CEO's letter to shareholders
Doktor.se has published its letter to shareholders for the first half of 2026, and there is plenty to be pleased about. The company is delivering growth and improved profitability – ahead of budget on both counts – and has also secured new financing of SEK 1.5 billion from…
Doktor.se: Strongest quarter since its founding
Q1 2026 was Doktor.se's strongest quarter since its founding. Group revenue came in at 470 MSEK, around 5% above budget. EBITDA on an IFRS basis amounted to 46 MSEK — almost 30% above plan.
CEO report Jan–Feb 2026. Doktor.se.
Doktor.se today published its CEO report for January–February 2026, and it is a strong report on most counts. Below is what we consider most relevant.
Doktor.se in the catalogue
The company's own page has the share price, valuation, owners and the reports published for trading.
Go to Doktor.seOther news about Doktor.se
4 postsEverything we have written about Doktor.se, newest first. The reports stand on their own at the top and the rest of the news below them — acquisitions, share issues, partnerships and what the company itself has announced. You will find the share price, valuation and company data on the company's own page.
Martin Lindman, CEO of Doktor.se: From minus 147 million to IPO-ready
EBITDA of minus 147 million. An IPO that never happened. A pandemic in the middle of the build-up. Martin Lindman went from professional hockey player to building one of Europe's largest digital healthcare companies — and today Doktor.se has revenue of SEK 1.8 billion, is…
Doktor.se reports improved profitability, strong YoY development and confirmed IPO ambition
Doktor.se ended 2025 with a clear year-on-year improvement and strong operating momentum, despite a politically challenging market climate. The company beat its communicated forecast and delivered a particularly strong fourth quarter.
Doktor.se closes oversubscribed share issue – aims for expansion
Doktor.se reports that it has now completed its latest funding round of around 250 MSEK, with very strong interest. The share issue was 2x oversubscribed, and over 80% of the company's existing shareholders took part.
New share issue and IPO plans – Doktor.se prepares for its next phase
LTM as of 31 July 2025: Revenue 1,821 MSEK; adjusted EBITDA 186 MSEK (10% margin).
